Efficacy of Different Doses of Daunorubicin Induced Chemotherapy in Patients with Newly Diagnosed Primary Acute Myeloid Leukemia Under 65 Years Old.
10.19746/j.cnki.issn.1009-2137.2021.04.009
- Author:
Shuai-Ge GONG
1
;
Fu-Jue WANG
1
;
Shuo-Ting WANG
1
;
Qin ZHENG
2
;
Xiao SHUAI
1
;
Hong-Bing MA
1
;
Li ZHANG
1
;
Xin-Chuan CHEN
1
;
Yu WU
1
;
Yong-Qian JIA
3
Author Information
1. Department of Hematology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.
2. Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.
3. Department of Hematology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China,E-mail: jia_yq@scu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Aged;
Antineoplastic Combined Chemotherapy Protocols;
Cytarabine/therapeutic use*;
Daunorubicin;
Humans;
Induction Chemotherapy;
Leukemia, Myeloid, Acute/drug therapy*;
Remission Induction;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(4):1071-1079
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the efficacy and safety of different doses of daunorubicin combined with a standard dose of cytarabine as induction chemotherapy in newly diagnosed primary acute myeloid leukemia (AML) patients.
METHODS:The clinical data and outcome were retrospectively analyzed in 86 newly diagnosed primary AML patients who were under 65 years old and treated with daunorubicin combined with cytarabine (DA regimen) at West China Hospital of Sichuan University from January 2017 to June 2019. Patients were divided into 2 groups based on the dose of daunorubicin they received, 35 cases in the escalated-dose group ［75 mg/(m
RESULTS:Median follow-up time of all the patients was 15 months. The CR rate and MRD
CONCLUSION:The escalated dose of daunorubicin can induce higher complete remission rate, deeper remission and longer duration of remission without increasing adverse events in newly diagnosed primary AML patients.
